“Guide to facilitate the implementation of the WHO/UNICEF “Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines” for Africa
Reports of antimicrobial-resistant (AMR) microorganisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. In Africa, AMR has already been documented to be a problem for human immunodeficiency virus (HIV) and the pathogens that cause mala...ria, tuberculosis (TB), typhoid, cholera, meningitis, gonorrhoea and dysentery. Recognizing the urgent need for action, the 2016 United Nations (UN) General Assembly approved a resolution to ensure sustained and effective global action to address AMR.
more
In an effort to limit transmission and achieve pandemic control on the continent, Africa CDC is proposing the following measures to be taken by all Member States:
Remain vigilant
Countries should adapt or adopt best practices, strategies, guidelines and recommendations proposed by the Africa CDC... and World Health Organization (WHO), aimed at limiting transmission. Measures taken should strike a balance between saving lives and minimizing the impact of the pandemic on the economy and social wellbeing of citizens.
more
Mars 2020. Recommendations selon les differentes phases
Internationally, there is a growing concern over antimicro-bial resistance (AMR) which is currently estimated to ac-count for more than 700,000 deaths per year worldwide. If no appropriate measures are taken to halt its pro-gress, AMR will cost approximately 10 million lives andabout US$100 trillion... per year by 2050. In contrast tosome other health issues, AMR is a problem that con-cerns every country irrespective of its level of incomeand development as resistant pathogens do not respect borders.Despite the threat presented by AMR, the 2014 WorldHealth Organization (WHO) and the recent O’Neill re-port describe significant gaps in surveillance, standardmethodologies and data sharing. The 2014 WHOreport identified Africa and South East Asia as the regions without established AMR surveillance systems.
Tadesseet al. BMC Infectious Diseases (2017) 17:616 DOI 10.1186/s12879-017-2713-1
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more
WHO Regional Office for Africa
Technical Update
Areas of Africa endemic for Buruli ulcer (BU), caused by Mycobacterium ulcerans, also have a high prevalence of human immunodeficiency virus (HIV), with adult prevalence rates between 1% and 5% (Maps). However, there is limited information on the prevalence of BU–HIV coinfection.... Preliminary
evidence suggests that HIV infection may increase the risk of BU disease (1–3). In the Médecins Sans Frontières project in Akonolinga, Cameroon, HIV prevalence was approximately 3–6 times higher among BU patients than the regional estimated HIV prevalence (2). Similarly in Benin and Ghana, BU
patients were 8 times and 3 times respectively more likely to have HIV infection than those without BU (1, 3). Further study is needed to clarify this association and enhance knowledge about the prevalence ofBU–HIV coinfection in endemic areas.
more
A varíola dos macacos é uma doença infeciosa emergente causada por um vírus transmitido aos humanos por animais infetados, na sua maioria roedores. Pode ser propagado a outras pessoas, mas a transmissão de pessoa para pessoa, isoladamente, não pode facilmente sustentar um surto. A apresentaç...o clínica é semelhante à observada no passado com a varíola, mas menos grave. A varíola foi erradicada mundialmente em 1980; no entanto, a varíola dos macacos ainda ocorre esporadicamente em partes da África Central e Ocidental, perto das florestas tropicais húmidas. Normalmente, a mortalidade nos surtos da varíola dos macacos tem sido de 1 a 10%, mas com os cuidados adequados, a maioria dos doentes recupera. Este curso fornece uma introdução geral à varíola dos macacos e destina-se aos profissionais de saúde responsáveis pela prevenção e controlo da varíola dos macacos.
more
The Global Vaccine Action Plan (GVAP) 2011-2020, endorsed by Member States during the May 2012 World Health Assembly, has set ambitious targets to improve access to immunization and tackle vaccine-preventable diseases. This responsibility has been translated into firm commitments in February 2016, t...hrough the signature of the Addis Declaration on Immunization (ADI) by African Ministers and subsequently endorsed by the Heads of States from across Africa at the 28th African Union Summit held in January 2017. This commitment from the highest level of government comes as a catalyst to immunization efforts on the continent to deliver on the promise of universal immunization
more
Response to the tropical cyclone in southern Africa
Ebola virus disease outbreak in the Democratic Republic of the Congo
Meningitis outbreak in Togo
Lassa fever outbreak in Liberia.
West Africa is experiencing the largest, most severe, most complex outbreak of Ebola virus disease in history. On 11 August 2014, WHO convened a consultation where the participants concluded that in the particular context of the current Ebola outbreak in West Africa, it is ethically acceptable to of...fer unproven interventions that have shown promising results in the laboratory and in animal models but have not yet been evaluat-
ed for safety and efficacy in humans as potential treatment or prevention
more
The Ebola outbreak in West Africa is not over. WHO continues to work with governments and the international health community to get to zero cases and help countries stay there.
La viruela del mono es una enfermedad transmisible emergente causada por un virus que se transmite a los seres humanos a partir de animales infectados, generalmente roedores. Puede contagiarse a otras personas, pero la transmisión de persona a persona por sí sola no es capaz de mantener un brote. ...La presentación clínica es similar a la observada en el pasado con la viruela, pero menos grave. La viruela fue erradicada en el mundo en 1980; sin embargo, la viruela del mono sigue produciéndose esporádicamente en partes de África Central y Occidental, cerca de las selvas tropicales. Normalmente, la letalidad en los brotes de viruela del mono ha sido del 1 al 10%, pero con los cuidados adecuados, la mayoría de los pacientes se recupera. Este curso ofrece una introducción general a la viruela del mono y está dirigido al personal sanitario responsable de la prevención y el control de la viruela del mono.
more
The World Health Organization's Regional Office for Africa webpage on diabetes provides an overview of the disease's impact in the African Region. It highlights that diabetes is a serious, chronic, and costly condition, with projections estimating cases to rise to 23.9 million by 2030. The page outl...ines risk factors such as physical inactivity, overweight and obesity, tobacco use, and diets high in unhealthy fats and calories. It also discusses the three main types of diabetes: type 1, type 2, and gestational diabetes. Recent surveys indicate that up to 15% of adults aged 25 to 64 in the region have diabetes, with many unaware of their condition. The lack of access to proper treatment and medications, especially insulin, often leads to complications like neurological, vascular, or visual disorders, heart disease, stroke, lower limb amputation, and kidney failure.
more
Ebola disease and Marburg disease outbreaks continue to occur in Africa, with increased frequency. In addition to resulting in high mortality and morbidity, the outbreaks generate fear and mistrust about the response activities within the communities affected.
Infection prevention and control (IP...C) is a key pillar in the outbreak response; adherence to IPC practices can prevent and control transmission of infections to health and care workers, patients and their family members.
During the 2014-2016 West African Ebola disease outbreak, there was an urgent need for rapid IPC guidance to help support ministries of health, health-care providers and non-governmental organizations (NGOs). In response, WHO produced several documents related to the outbreak based on expert opinion, including IPC-specific documents and documents on clinical management that also referenced key IPC principles and practices. Since that time, many practices in the field have become institutionalized.
more
Weekly bulletins on outbreaks and other emergencies in the WHO Africa Region.
Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and
blindness. But the epidemiological situation has improved dramatically over the last two decades.... Community directed treatment with ivermectin has effectively brought the disease under control in most endemic areas where onchocerciasis is no longer a public health risk.
more